| Literature DB >> 29085195 |
Xing Wang1, Chun-Lu Tan1, Hai-Yu Song1, Qiang Yao2, Xu-Bao Liu3.
Abstract
AIM: To describe the indications, technique and outcomes of the novel surgical procedure of duodenum and ventral pancreas preserving subtotal pancreatectomy (DVPPSP).Entities:
Keywords: Low-grade malignant neoplasm; Quality of life; Subtotal pancreatectomy; Ventral pancreas preserving
Mesh:
Year: 2017 PMID: 29085195 PMCID: PMC5643271 DOI: 10.3748/wjg.v23.i35.6457
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Preoperative computed tomography view of a 26-year-old female patient with a diagnosis of pseudo-papillary tumors. The figure shows that the lesion occupied the body and neck region with necrosis of the tail on preoperative computed tomography imaging. Normal pancreatic tissue is observed in the ventral pancreas region.
Figure 2Intraoperative view of duodenum and ventral pancreas preserving subtotal pancreatectomy. A: Superior mesenteric vein; B: Ventral pancreas. Black arrow: intrapancreatic bile duct; White arrow: gastroduodenal artery.
Figure 3Preoperative magnetic resonance imaging view of a 71-year-old female patient with diagnosis of MD-IPMN. The figure shows that the lesion involves the whole dorsal duct (including Santorini duct). The diameter of ventral pancreatic duct is normal on the MRCP image.
Preoperative characteristics and final pathologic features of 23 patients in the duodenum and ventral pancreas preserving subtotal pancreatectomy and total pancreatectomy groups n (%)
| Age (range, yr) | 49 ± 16.9 (24-71) | 56 ± 10.1 (40-70) | 0.256 |
| Gender (%) | 0.680 | ||
| Male | 4 (40) | 7 (54) | |
| Female | 6 (60) | 6 (46) | |
| Major comorbidity | |||
| CAD | 0 | 1 | 1.000 |
| COPD | 1 | 2 | 1.000 |
| DM | 2 | 3 | 1.000 |
| Hypertension | 3 | 3 | 1.000 |
| Preoperative symptoms | |||
| Incidental | 0 | 2 (15) | 0.486 |
| Symptomatic (%) | 10 (100) | 11 (85) | |
| Abdominal pain | 4 (40) | 6 (55) | 1.000 |
| Pancreatitis | 1 | 4 | 0.339 |
| Weight loss | 1 | 4 | 0.339 |
| Gastrointestinal symptoms | 4 | 3 | 0.65 |
| ASA score | 1.000 | ||
| I/II | 7 | 10 | |
| III | 3 | 3 | |
| Pathology (%) | 0.411 | ||
| IPMN | 6 (60) | 11 (85) | |
| Low-grade moderate-grade dysplasia | 2 | 1 | 0.515 |
| High-grade dysplasia | 3 | 4 | 0.644 |
| Invasive carcinoma | 1 (16.7) | 5 (45.5) | 0.333 |
| Neuroendocrine tumor | 2 | 1 | |
| G 2 | 2 | 1 | 1.000 |
| SPT | 2 | 1 | |
| Total invasive malignancy | 1 (10) | 5 (38.5) | 0.179 |
CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; IPMN: Intraductal papillary mucinous neoplasm; SPT: Pseudo-papillary tumor; DVPPSP: Duodenum and ventral pancreas preserving subtotal pancreatectomy.
Intraoperative and postoperative outcomes of 23 patients after duodenum and ventral pancreas preserving subtotal pancreatectomy and total pancreatectomy
| Intraoperative transfusion (U) | 0.20 ± 0.63 (0-2) | 0.54 ± 1.05 (0-3) | 0.379 |
| Operative time (min) | 232 ± 19.6 (215-255) | 335 ± 32.3 (280-400) | < 0.001 |
| Postoperative characteristics | |||
| DGE | 0 | 1 | 1.000 |
| Biliary fistula | 0 | 1 | 1.000 |
| Pancreatic fistula (B and C) | 0 | 0 | — |
| Overall morbidity | 2 | 5 | 0.405 |
| Major morbidity (≥ grade 3) | 1 | 2 | 1 |
| Reoperation | 0 | 0 | — |
| Readmission (30 d) | 0 | 0 | — |
| LOS | 9.7 ± 3.8 (7-20) | 11.7 ± 5.2 (8-26) | 0.318 |
| Mortality | 0 | 0 | — |
| Recurrence | 2 (20%) | 5 (38.5%) | 0.405 |
| IPMN | 2/6 | 5/11 | 1.000 |
The recurrences of 2 patients in the DVPPSP group and 5 patients in the TP group occurred after surgery for IPMN. DGE: Delayed gastric emptying; LOS: Length of postoperative stay; DVPPSP: Duodenum and ventral pancreas preserving subtotal pancreatectomy.
Postoperative condition of supplementary therapy of 23 patients after duodenum and ventral pancreas preserving subtotal pancreatectomy and total pancreatectomy
| Enzymes replacement (cps/d) | 0.9 ± 2.0 | 9.2 ± 2.2 | < 0.001 |
| Total insulin dose (U/d) | 6.4 ± 14.0 | 29.7 ± 9.3 | < 0.001 |
| Diarrhea or steatorrhea | 2 | 4 | 0.660 |
| Hyperglycemia | 0 | 5 | 0.046 |
TP: Total pancreatectomy; DVPPSP: Duodenum and ventral pancreas preserving subtotal pancreatectomy.
Postoperative condition of diabetes of 10 patients in the duodenum and ventral pancreas preserving subtotal pancreatectomy group
| New-onset diabetes | 0 / 7 |
| Worsen diabetes | 1/3 |
| Diet to oral medication | — |
| Diet to insulin | — |
| Oral medication to insulin | 1/3 |
There was 3 out of 10 patients in DVPPSP group who had diabetes before surgery and were treated by oral medicine. DVPPSP: Duodenum and ventral pancreas preserving subtotal pancreatectomy.
Quality of lives after duodenum and ventral pancreas preserving subtotal pancreatectomy and total pancreatectomy
| Functional scale | |||
| Physical | 95.0 ± 9.3 (80-100) | 97.5 ± 7.1 (80-100) | 0.554 |
| Working ability | 100 | 100 | — |
| Cognitive | 100 | 100 | — |
| Emotional | 98.4 ± 2.9 (93.8-100) | 92.2 ± 8.0 (75-100) | 0.057 |
| Social | 95.8 ± 7.7 (83.3-100) | 85.4 ± 10.7 (66.7-100) | 0.042 |
| Global QoL | 96.9 ± 6.2 (83.3-100) | 88.5 ± 8.9 (75-100) | 0.047 |
| Symptom scale | |||
| Fatigue | 4.2 ± 8.3 (0-22.2) | 11.1 ± 11.7 (0-33.3) | 0.196 |
| Nausea and vomiting | 0 | 6.3 ± 12.4 (0-33.3) | 0.197 |
| Pain | 0 | 0 | — |
| Appetite loss | 0 | 20.8 ± 24.8 (0-66.7) | 0.049 |
| Dyspnea | 0 | 0 | — |
| Sleep disturbance | 4.2 ± 11.8 (0-33.3) | 12.5 ± 17.2 (0-33.3) | 0.281 |
| Constipation | 0 | 4.2 ± 11.8 (0-33.3) | 0.351 |
| Diarrhea | 4.2 ± 11.8 (0-33.3) | 12.5 ± 24.8 (0-66.7) | 0.405 |
| Financial strain | 0 | 8.3 ± 15.4 (0-33.3) | 0.170 |
TP: Total pancreatectomy; QoL: Quality of life; DVPPSP: Duodenum and ventral pancreas preserving subtotal pancreatectomy.